18F-FDG PET在淋巴瘤分期和治疗反应评价中的价值

赵晋华

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2004,  28 > 5: (210-212)  
引用本文:
shu
Citation:
shu

18F-FDG PET在淋巴瘤分期和治疗反应评价中的价值

  • 200080 上海, 上海交通大学附属第一人民医院核医学科

  • 中图分类号: R817.4

18F-FDG PET in the staging and evaluating of the response to therapy for lymphoma

  • Department of Nuclear Medicine, The First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China

  • CLC number: R817.4

  • 摘要: 18F-FDG PET显像对淋巴瘤的诊断、分期作用显著,对淋巴瘤病灶的探测灵敏度和准确性高于67Ga显像。在化疗过程中和化疗后持续18F-FDG PET阳性对预测复发有高灵敏度。治疗结束时18F-FDG PET阴性提示患者预后好。与其他常规显像相比,18F-FDG PET在监测淋巴瘤疗效、判断治疗反应方面有独特优势。
    Abstract: 18F-FDG PET is an important imaging technique in the stage of patients with lymphoma and more sensitive and accurate than gallium scintigraphy. Persistently positive PET imaging during and after chemotherapy have a high sensitivity for predicting subsequent relapse. A negative PET imaging at the end of therapy provides favorable prognostic information. Compared to other conventional imaging modalities, 18F-FDG PET significantlyimproves the accuracy of imaging tumors in initial staging, and monitoring of therapy response of lymphoma.
  • [1] Elstrom R,Guan L,Baker G,et al.Utility of FDG-PET scanning inlymphoma by WHO classification[J].Blood,2003,101(10):3875-3876.
    [2] Hoffmann M,Kletter K,Becherer A,et al.18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma[J]. Oncology,2003,64(4):336-340.
    [3] Jerusalem G,Beguin Y,Najjar F,et al.Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)[J].Ann Oncol,2001,12(6):825-830.
    [4] Najjar F,Hustinx R,Jerusalem G,et al.Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL)[J].Cancer Biother Radiopharm,2001,16(4):297-304.
    [5] Bangerter M,Moog F,Buchmann I,et al.Whole-body 2-[18F]-fluo-ro-2-deoxy-D-glucose positron emission tomography (FDG-PET)for accurate staging of Hodgkin's disease[J].Ann Oncol,1998,9(10):1117-1122.
    [6] Wirth A,Seymour JF,Hicks RJ,et al.Fluorine-18 fluorodeoxyglu-cose positron emission tomography,gallium-67 scintigraphy,and conventional staging for Hodgkin's disease and non-Hodgkin's lym-phoma[J].Am J Med,2002,112(4):262-268.
    [7] Buchmann I,Reinhardt M,Elsner K,et al.2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma.A bicenter trial[J].Cancer,2001,91(5):889-899.
    [8] Moog F,Bangerter M,Kotzerke J,et al.18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lym-phomatous bone marrow[J].J Clin Oncol,1998,16:603-609.
    [9] Hueltenschmidt B,Sautter-Bihl ML,Lang O,et al.Whole body positron emission tomography in the treatment of Hodgkin disease[J].Cancer,2001,91(2):302-310.
    [10] Kostakoglu L,Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast,lung,and colorectal carcino-ma[J].J Nucl Med,2003,44(2):224-239.
    [11] Kostakoglu L,Coleman M,Leonard JP,et al.PET predicts prognosis after1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease[J].J Nucl Med,2002,43(8):1018-1027.
    [12] Jerusalem G,Beguin Y,Fassotte MF,et al.Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging[J].Blood,1999,94(2):429-433.
    [13] Spaepen K,Stroobants S,Dupont P,et al.Prognostic value of-positron emission tomography (PET) with fluorine-18 fluorodeoxyglu-cose ([18F]FDG)after first-line chemotherapy in non-Hodgkin's lymphoma:is[18F]FDG-PET a valid alternative toconventional diagnostic methods?[J].J Clin Oncol,2001,19(2):414-419.
    [14] Becherer A,Mitterbauer M,Jaeger U,et al.Positron emission tomography with[18F]2-fluoro-D-2-deoxyglucose (FDG-PET)predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation[J].Leukemia,2002,16(2):260-267.
    [15] Spaepen K,Stroobants S,Dupont P,et al.Prognostic value of pretransplantation positron emission tomography using fluorine18-fluo-rodeoxyglucose in patients with aggressive lymphoma treated with-high-dose chemotherapy and stem cell transplantation[J].Blood,2003,102(1):53-59.
  • [1] 华逢春 , 管一晖 , 赵军 . 18F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用. 国际放射医学核医学杂志, 2005, 29(5): 216-219,226.
    [2] 吴湖炳 . 18F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 205-209.
    [3] 刘建军 , 黄钢 . 18F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究. 国际放射医学核医学杂志, 2005, 29(5): 213-216.
    [4] 王峰 . 18F-FDG PET对原发性食管癌和复发性食管癌的诊断价值. 国际放射医学核医学杂志, 2004, 28(1): 15-17.
    [5] 蔡莉 , 李彦生 . 氟代脱氧葡萄糖与氨基酸PET在脑肿瘤中的对比研究. 国际放射医学核医学杂志, 2005, 29(1): 10-14.
    [6] 袁志斌 . 正电子肿瘤阳性显像剂18F-AMT. 国际放射医学核医学杂志, 2002, 26(5): 193-195.
    [7] 丁晓芳 , 肖晓燕 , 柳江燕 . PET/CT在结外NK/T细胞淋巴瘤诊治中的应用进展. 国际放射医学核医学杂志, 2021, 45(12): 789-794. doi: 10.3760/cma.j.cn121381-202012013-00111
    [8] 张立颖 . 18F-FDG PET显像在恶性淋巴瘤中的应用. 国际放射医学核医学杂志, 2001, 25(1): 10-12.
    [9] 孙建鹰 , 杜明华 . 18F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的. 国际放射医学核医学杂志, 2008, 32(5): 290-294.
    [10] 袁志斌 . 11C-胆碱和18F-FDG在肿瘤PET中的比较. 国际放射医学核医学杂志, 2003, 27(6): 251-254.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1339
  • HTML全文浏览量:  99
  • PDF下载量:  2
出版历程
  • 收稿日期:  2004-06-18

18F-FDG PET在淋巴瘤分期和治疗反应评价中的价值

  • 200080 上海, 上海交通大学附属第一人民医院核医学科
  • 收稿日期: 2004-06-18

摘要: 18F-FDG PET显像对淋巴瘤的诊断、分期作用显著,对淋巴瘤病灶的探测灵敏度和准确性高于67Ga显像。在化疗过程中和化疗后持续18F-FDG PET阳性对预测复发有高灵敏度。治疗结束时18F-FDG PET阴性提示患者预后好。与其他常规显像相比,18F-FDG PET在监测淋巴瘤疗效、判断治疗反应方面有独特优势。

English Abstract

    全文HTML

参考文献 (15)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net